← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
The University Of Queensland
$31,961,604
Total funding
53
Grants
Funding over time
peak $7.7M · FY2010–25$10M$7.5M$5M$2.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$31,961,604 · 53
By mechanism
—$31,961,604 · 53
Investigators at The University Of Queensland
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
NEXT-GENERATION PEPTIDE-BASED MEDICINES FOR MALARIA$2,383,881
· FY2022 · Department of the Army
DRUGS FROM BUGS: DEVELOPING NEW INFLAMMATORY BOWEL DISEASE DRUGS FROM GUT BACTERIA-DERIVED BIOACTIVES$1,750,367
· FY2021 · Defense Health Agency
DISCOVERY OF NEW TREATMENTS AND BIOMARKERS FOR NEUROGENIC HETEROTOPIC OSSIFICATIONS FOLLOWING SPINAL CORD INJURIES$1,460,812
· FY2021 · Defense Health Agency
SPINEPASS: SPINE SELF-MANAGEMENT TECHNIQUES FOR PERSISTENT HEADACHE AFTER CONCUSSION-PHYSICAL THERAPY TARGETING AUTONOMIC AND DURA MATER FUNCTION$1,339,480
· FY2024 · Defense Health Agency
TOPICAL VENOM ACTIVATED HYDROGEL HEMOSTATIC (PROCOAGULANT + ANTIFIBRINOLYTIC) AGENT$1,218,626
· FY2022 · Defense Health Agency
PREDICTING EARLY-STAGE MELANOMA AT HIGH RISK OF RECURRENCE THROUGH MULTIOMICS PROFILING$1,156,726
· FY2025 · Defense Health Agency
A FIRST-IN-CLASS CALCIUM CHANNEL INHIBITOR FOR THE TREATMENT OF ADVANCED METASTATIC PROSTATE CANCERS RESISTANT TO NEXT-GENERATION ANTIANDROGEN THERAPY$1,120,707
· FY2025 · Defense Health Agency
PROTEOMIC BIOMARKERS FOR ALS DISEASE PROGNOSIS AND PROGRESSION MONITORING.$1,117,328
· FY2025 · Defense Health Agency
EXPLOITING THE REMODELING OF CA2+ SIGNALING IN BREAST CANCER CELL MICROENVIRONMENTS TO CONTROL METASTASIS AND TO SPECIFICALLY TARGET BRAIN METASTASES$1,077,996
· FY2017 · Department of the Army
PRECLINICAL VALIDATION OF A NOVEL DRUG LEAD TO TREAT TUBERCULOSIS$1,066,074
· FY2018 · Department of the Army
UNDERSTANDING ACUTE TO CHRONIC BACK PAIN PATHWAYS AND TESTING NEW SOLUTIONS. NEW AWARD.$1,010,639
· FY2020 · Defense Health Agency
EXPLOITING THE REMODELING OF CA2+ SIGNALING IN BREAST CANCER CELL MICROENVIRONMENTS TO CONTROL METASTASIS AND TO SPECIFICALLY TARGET BRAIN METASTASES$990,460
· FY2017 · Department of the Army
ENDOMETRIOSIS SUSCEPTIBILITY GENES IN ENDOMETRIAL STEM/PROGENITOR CELLS$789,363
· FY2019 · Department of the Army
ENHANCEMENT OF NATURAL KILLER CELL FUNCTION FOR THERAPEUTIC TARGETING AND ELIMINATION OF METASTATIC BREAST CANCER$763,547
· FY2021 · Defense Health Agency
UNDERSTANDING THE ROLE OF IMMATURE MYELOID CELLS IN EARLY MELANOMA ESTABLISHMENT$744,744
· FY2022 · Department of the Army
MELANOMA RESEARCH PROGRAM$744,298
· FY2022 · Defense Health Agency
THERAPEUTIC INHIBITION OF NEUTROPHIL ACTIVITY AS A DISEASE-MODIFYING TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS$731,009
· FY2022 · Defense Health Agency
DANGER SIGNALING, TRAUMATIC BRAIN INJURY, AND EPILEPTOGENESIS.$705,615
· FY2021 · Defense Health Agency
DECIPHERING AND INTERCEPTING MESSAGES BETWEEN CANCER CELLS AND CELLS IN THE BREAST CANCER MICROENVIRONMENT: ROLES FOR INTRACELLULAR CALCIUM SIGNALING$695,563
· FY2020 · Defense Health Agency
MECHANISMS AND TREATMENTS OF HETEROTOPIC OSSIFICATION FOLLOWING SPINAL CORD INJURIES$690,511
· FY2015 · Department of Defense